Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 3 4Phase 1/2 3Phase 2/3 2Phase 4 1Phase 1 1

Status

Completed 113Terminated 33Recruiting 19Active not recruiting 15Withdrawn 14Unknown 6Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Ann Arbor Stage II Mantle Cell Lymphoma 1

Interventions

Cyclophosphamide 22fludarabine 17Specimen Handling 13Nivolumab 10pembrolizumab 9Magnetic Resonance Spectroscopy 9Radiotherapy 6Cisplatin 6fludarabine phosphate 5Interleukin-2 5Injections 5Doxorubicin 5tislelizumab 4daratumumab 4Paclitaxel 4Ipilimumab 4Immune Checkpoint Inhibitors 4Drug Therapy 4Dexamethasone 4Carboplatin 4Biopsy 4venetoclax 3trastuzumab deruxtecan 3toripalimab 3ruxolitinib 3X-Rays 3Vincristine 3Rituximab 3Radiosurgery 3Prednisone 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Not yet recruiting × Cytarabine × Clear all
NCT07444710 2026-05-13

Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma

National Cancer Institute (NCI)

Phase 1 Not yet recruiting
16 enrolled
Lymphoid

Ann Arbor Stage II Mantle Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡